Dr. Hurvitz on Treatment Options for HER2-Positive Breast Cancer

Sara Hurvitz, MD, Associate Professor of Medicine at UCLA, discusses treatment options for patients with HER2-positive breast cancer.

According to Hurvitz, the treatments for HER2-positive breast cancer have evolved over the past 5 years. There is now refined criteria for treatments that physicians should be giving in the first-line and second-line settings.

The standard of care for the first-line setting is trastuzumab (Herceptin) and pertuzumab (Perjecta) with a taxane to be given for 4 to 6 cycles, explains Hurvitz.